CMPS Stock Forecast 2025-2026
Distance to CMPS Price Targets
CMPS Price Momentum
10 Quality Stocks Worth Considering Now
Researching Compass (CMPS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CMPS and similar high-potential opportunities.
Latest CMPS Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, CMPS has a bullish consensus with a median price target of $12.00 (ranging from $11.00 to $45.00). Currently trading at $2.98, the median forecast implies a 302.7% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 1,410.1% upside. Conversely, the most conservative target is provided by Paul Matteis at Stifel, suggesting a 269.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CMPS Analyst Ratings
CMPS Price Target Range
Latest CMPS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CMPS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $45.00 |
| Feb 28, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $15.00 |
| Feb 27, 2025 | Stifel | Paul Matteis | Buy | Initiates | $11.00 |
| Feb 13, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $45.00 |
| Jan 15, 2025 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $18.00 |
| Nov 1, 2024 | Maxim Group | Jason McCarthy | Buy | Maintains | $12.00 |
| Nov 1, 2024 | RBC Capital | Leonid Timashev | Outperform | Maintains | $18.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $60.00 |
| Sep 10, 2024 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $23.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Aug 23, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $120.00 |
| Aug 2, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $48.00 |
| Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $120.00 |
| Jul 23, 2024 | RBC Capital | Leonid Timashev | Outperform | Initiates | $23.00 |
| Jun 21, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| May 13, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $120.00 |
| Apr 30, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Apr 19, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Apr 18, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Apr 1, 2024 | Morgan Stanley | Vikram Purohit | Overweight | Initiates | $30.00 |
Compass Pathways plc (CMPS) Competitors
The following stocks are similar to Compass based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Compass Pathways plc (CMPS) Financial Data
Compass Pathways plc has a market capitalization of $276.17M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -81.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Compass Pathways plc (CMPS) Business Model
About Compass Pathways plc
Develops innovative therapies for mental health disorders.
The company focuses on the development of psilocybin therapy for major depressive disorder, aiming to provide effective alternatives to traditional treatments. It collaborates with experts and institutions to conduct rigorous clinical trials, ensuring the safety and efficacy of its therapies, thereby generating revenue through potential drug approvals and market sales.
Based in London, Compass Pathways is positioned at the forefront of psychedelic medicine, addressing significant unmet needs in mental health care through science-backed innovation.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
166
CEO
Mr. Kabir Kumar Nath M.A., M.B.A.
Country
United Kingdom
IPO Year
2020
Website
compasspathways.comCompass Pathways plc (CMPS) Latest News & Analysis
Compass Pathways plc (Nasdaq: CMPS) announced results from the COMP004 study, indicating that a single 25 mg dose of COMP360 psilocybin showed positive effects over 52 weeks for treatment-resistant depression.
Positive results from the COMP004 study could enhance Compass Pathways' credibility and market position, potentially boosting stock value and investor interest in psychedelic therapies for TRD.
Compass Pathways plc (Nasdaq: CMPS) will present at the Stifel Virtual CNS Forum on March 18, 2025, at 11:30 am ET. A live webcast will be available on their website, with a replay for 30 days.
Compass Pathways' presentation at a major forum highlights its commitment to mental health innovation, potentially boosting investor confidence and interest in the biotech sector.
COMPASS Pathways plc (NASDAQ:CMPS) will hold its Q4 2024 earnings conference call on February 27, 2025, at 8:00 AM ET, featuring key executives and analysts from various firms.
The Q4 2024 earnings call for COMPASS Pathways will provide insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights
1 month agoCompass Pathways plc (Nasdaq: CMPS) reported Q4 and full year 2024 financial results, noting progress in its phase 3 COMP360 program for treatment-resistant depression, with top-line data expected soon.
Compass Pathways' positive update on its pivotal phase 3 trial for treatment-resistant depression could drive investor confidence, impacting stock performance and market sentiment in biotech.
Stifel has begun coverage of Compass Pathways plc (CMPS), highlighting a favorable outlook for the psychedelics sector.
Stifel's coverage initiation on Compass Pathways signals potential growth in the psychedelics sector, highlighting emerging investment opportunities in mental health treatments.
Compass Pathways has $165.1 million in cash reserves, providing 4-6 quarters of runway. Its COMP360 shows promise for treating treatment-resistant depression and PTSD.
Compass Pathways' strong cash reserves and promising clinical data for COMP360 in treating depression and PTSD position it favorably, despite sector challenges, suggesting potential for growth and investment returns.
Frequently Asked Questions About CMPS Stock
What is Compass Pathways plc's (CMPS) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Compass Pathways plc (CMPS) has a median price target of $12.00. The highest price target is $45.00 and the lowest is $11.00.
Is CMPS stock a good investment in 2025?
According to current analyst ratings, CMPS has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CMPS stock?
Wall Street analysts predict CMPS stock could reach $12.00 in the next 12 months. This represents a 302.7% increase from the current price of $2.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Compass Pathways plc's business model?
The company focuses on the development of psilocybin therapy for major depressive disorder, aiming to provide effective alternatives to traditional treatments. It collaborates with experts and institutions to conduct rigorous clinical trials, ensuring the safety and efficacy of its therapies, thereby generating revenue through potential drug approvals and market sales.
What is the highest forecasted price for CMPS Compass Pathways plc?
The highest price target for CMPS is $45.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 1,410.1% increase from the current price of $2.98.
What is the lowest forecasted price for CMPS Compass Pathways plc?
The lowest price target for CMPS is $11.00 from Paul Matteis at Stifel, which represents a 269.1% increase from the current price of $2.98.
What is the overall CMPS consensus from analysts for Compass Pathways plc?
The overall analyst consensus for CMPS is bullish. Out of 12 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are CMPS stock price projections?
Stock price projections, including those for Compass Pathways plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
